Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

• DOI: 10.1186/s12967-016-1005-7
• Publication Date: 2016-09-02T09:50:21Z
• Authors: Luz M. Medrano; Norma Rallón; Juan Berenguer; María A. Jiménez-...; Vicente Soriano; Teresa Aldámiz-Ec...; Amanda Fernández-...; Marcial García; Francisco Tejerina; Isidoro Martínez; José M. Benito; Salvador Resino
• Keywords: Ledipasvir; Hepatitis C; Transient elastography; Pegylated interferon; Liver disease

TRIM5 and TRIM22 are restriction factors involved in innate immune response exhibit anti-viral activity. Single nucleotide polymorphisms (SNPs) at genes have shown to influence several viral infections such as human immunodeficiency virus (HIV), hepatitis B, well measles rubella vaccination. The aim of this study is analyze whether associated with liver fibrosis inflammation-related biomarkers pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV) therapy HIV/hepatitis C (HCV) coinfected patients. A retrospective was performed 319 patients who started pegIFNα/RBV therapy. Liver stage characterized 288 rs3824949 (rs1063303, rs7935564, rs7113258) were genotyped using the GoldenGate assay. primary outcomes were: a) significant (≥F2) evaluated by biopsy or transient elastography (liver stiffness values ≥7.1 Kpa); b) sustained virological (SVR) defined no detectable HCV load (<10 IU/mL) week 24 after end treatment. secondary outcome variable plasma chemokine levels. Patients GG genotype had higher SVR rate than CC/CG genotypes (p = 0.013), they increased odds achieving (adjusted ratio (aOR 2.58; p 0.012). rs1063303 proportion 0.021), having hepatic 2.19; 0.034). rs7113258 AT/AA TT 1.88; 0.041). haplotype conformed rs1063303_C rs7113258_A more frequent 0.018) significantly 2.80; 0.013). levels GRO-α arithmetic mean ((aAMR) 1.40; 0.011) MCP-1 (aAMR 1.61; 0.003). SNPs HIV/HCV Besides, SNP baseline circulating GRO MCP-1.